Soussy C J, Meyran M, Chanal M, Reverdy M E, Kitzis M D, Derlot E
Service de Bactériologie, CHU Henri Mondor, Créteil.
Pathol Biol (Paris). 1991 May;39(5):396-402.
Minimal inhibitory concentration (MIC) of ceftibuten (CBT) were evaluated by agar dilution for 1,416 bacterial strains isolated in 5 hospitals. For Enterobacteriaceae, MIC 50 and 90% were respectively (micrograms/ml): (I) Naturally non beta-lactamase producing species: E. coli 0.12-0.5, Shigella 0.06-0.12 and Salmonella 0.03-0.12, P. mirabilis 0.16-0.03. (II) Chromosomal penicillinase producing species: K. pneumoniae 0.03-0.5 and K. oxytoca 0.03-0.06. (III) Chromosomal cephalosporin producing species: E. cloacae and C. freundii 1- greater than 128: S. marcescens 0.25-2; indole + Proteus 0.06-0.12. Activity of CBT was not modified on plasmid mediated penicillinase producing strains; however, CBT was inactive on cephalosporinase hyperproducing strains, and its activity was variably reduced on broad spectrum beta-lactamases producing strains. CBT was inactive on P. aeruginosa (MIC greater than or equal to 32) and on A. baumannii (8- greater than 128). Haemophilus and Gonococci, regardless on beta-lactamase production status, were very susceptible to CBT (MIC 50 and 90%: 0.06-0.5 and 0.016-0.06); it is the same situation for Meningococci; B. catarrhalis was generally inhibited by 0.03 to 2 (strains susceptible to penicillin G) and 0.12 to 16 (strains resistant to penicillin G). CBT was inactive on Staphylococci. Enterococci and Streptococci B were generally resistant; Streptococci A, C, G were inhibited by low concentrations: 0.06 to 1 (MIC 50 and 90%: 0.25-0.5), whereas MIC for other Streptococci 0.12 to 128 (MIC 50 and 90%: 8-128) and for Pneumococci were 0.25 to 16 (4-8). These antibacterial properties particularly against Enterobacteriaceae placed CBT in excellent position among oral cephalosporins.
采用琼脂稀释法对5家医院分离出的1416株细菌进行了头孢布烯（CBT）的最低抑菌浓度（MIC）评估。对于肠杆菌科细菌，MIC50和90%分别为（微克/毫升）：（I）天然不产β-内酰胺酶的菌种：大肠杆菌0.12 - 0.5、志贺氏菌0.06 - 0.12、沙门氏菌0.03 - 0.12、奇异变形杆菌0.16 - 0.03。（II）产染色体青霉素酶的菌种：肺炎克雷伯菌0.03 - 0.5、产酸克雷伯菌0.03 - 0.06。（III）产染色体头孢菌素酶的菌种：阴沟肠杆菌和弗氏柠檬酸杆菌1 - 大于128；粘质沙雷氏菌0.25 - 2；吲哚阳性变形杆菌0.06 - 0.12。CBT对质粒介导的产青霉素酶菌株的活性未改变；然而，CBT对高产头孢菌素酶菌株无活性，且其活性在产广谱β-内酰胺酶菌株中不同程度降低。CBT对铜绿假单胞菌（MIC大于或等于32）和鲍曼不动杆菌（8 - 大于128）无活性。嗜血杆菌和淋球菌，无论β-内酰胺酶产生状态如何，对CBT都非常敏感（MIC50和90%：0.06 - 0.5和0.016 - 0.06）；脑膜炎球菌情况相同；卡他莫拉菌通常被0.03至2（对青霉素G敏感的菌株）和0.12至16（对青霉素G耐药的菌株）抑制。CBT对葡萄球菌无活性。肠球菌和B群链球菌通常耐药；A、C、G群链球菌被低浓度抑制：0.06至1（MIC50和90%：0.25 - 0.5），而其他链球菌的MIC为0.12至128（MIC50和90%：8 - 128），肺炎球菌的MIC为0.25至16（4 - 8）。这些抗菌特性，尤其是对肠杆菌科细菌的特性，使CBT在口服头孢菌素中处于优势地位。
